We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.20 | 0.49% | 41.11 | 41.3125 | 40.87 | 40.95 | 2,730,464 | 21:00:02 |
From Apr 2019 to Apr 2024
By Chris Wack
Agenus Inc. on Tuesday reported the triggering of a $15.1 million milestone payment from HealthCare Royalty Partners based on sales of GlaxoSmithKline's Shingrix vaccine exceeding $2 billion in 2019.
Agenus said its proprietary QS-21 Stimulon is a key component in GlaxoSmithKline's Shingrix vaccine, which has generated sales exceeding $2.3 billion in its second year after launch.
Agenus said it is due another milestone amounting to $25.5 million if Shingrix sales exceed $2.75 billion over four consecutive quarters before 2026.
Agenus shares were up 6% to $2.49 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
March 10, 2020 09:39 ET (13:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
